Challenge
Generalized Lipodystrophy (GL) is a rare disease that leaves one with little to no fat tissue. Lack of fat tissue leads to having little to no leptin, an important hormone that helps control metabolic processes in the body. Without enough leptin, people with GL can experience serious health complications and changes to their physical appearances. The road to diagnosis is often long and complicated. Myalept, made by Aegerion Pharmaceuticals, is a leptin replacement prescription medicine, used with a doctor-recommended diet, for people with GL. Our task was to develop key digital assets and communication tools that educate patients and healthcare providers about GL and Myalept.